Amgen (AMGN) currently presents as a for most investors, though it remains a top-tier choice for those seeking a mix of steady dividends and high-potential pipeline updates. As of late April 2026, the stock is navigating a transition from legacy blockbusters to next-generation therapies in obesity and oncology. Amgen Inc (AMGN) 30.22% since Jan 4, 2025 Closed: 23:00 • Disclaimer After hours: 03:00 Apr 27, 2026 Open342.35 Mkt cap$183.57B USD 52-wk high391.29 High348.04 P/E ratio23.91 52-wk low261.43 Div yield2.96% The Investment Thesis: Growth vs. Defense
The market is hyper-focused on MariTide , Amgen’s monthly-dose obesity candidate, which could disrupt the current weekly-dose market dominated by Eli Lilly and Novo Nordisk. is amgen a good stock to buy
In 2025, revenue grew 10% to $36.8 billion , with non-GAAP earnings per share (EPS) rising to $21.84 . Amgen (AMGN) currently presents as a for most
The company recently declared a $2.52 per share quarterly dividend, offering an attractive yield of approximately 2.9-3% . Defense The market is hyper-focused on MariTide ,